Jörg Mahlich
Jörg Mahlich
JNJ
Dirección de correo verificada de dice.hhu.de - Página principal
Título
Citado por
Citado por
Año
The determinants of pharmaceutical R&D expenditures: evidence from Japan
JC Mahlich, T Roediger-Schluga
Review of Industrial Organization 28 (2), 145-164, 2006
542006
Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany
J Zeidler, J Mahlich, W Greiner, S Heres
Applied health economics and health policy 11 (5), 509-521, 2013
392013
Economic burden of osteoporotic fractures in Austria
HP Dimai, K Redlich, M Peretz, F Borgström, U Siebert, J Mahlich
Health economics review 2 (1), 12, 2012
382012
Evaluating the concordance of physician judgments and patient preferences on AIDS/HIV therapy-a Discrete Choice Experiment
AC Mühlbacher, M Stoll, J Mahlich, M Nübling
Health economics review 3 (1), 30, 2013
332013
Patents and performance in the Japanese pharmaceutical industry: An institution-based view
JC Mahlich
Asia Pacific Journal of Management 27 (1), 99-113, 2010
332010
Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
J Mahlich, R Sruamsiri
Patient preference and adherence 10, 1509, 2016
282016
Pharmaceutical regulation in Europe and its impact on corporate R&D
S Eger, JC Mahlich
Health economics review 4 (1), 23, 2014
282014
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany-an application of the efficiency frontier approach
C Gissel, G Götz, J Mahlich, H Repp
BMC infectious diseases 15 (1), 297, 2015
272015
Unemployment, health, and education of HIV-infected males in Germany
M Groß, A Herr, M Hower, A Kuhlmann, J Mahlich, M Stoll
International journal of public health 61 (5), 593-602, 2016
232016
Innovation and technology in Korea: challenges of a newly advanced economy
J Mahlich, W Pascha
Springer Science & Business Media, 2007
232007
Vergleichbarkeit internationaler Arzneimittelpreise
J Mahlich, J Sindern, M Suppliet
Perspektiven der Wirtschaftspolitik 16 (2), 164, 2015
222015
Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents
J Mahlich, R Sruamsiri
Current medical research and opinion 33 (1), 101-107, 2017
212017
Erfolgsfaktoren von forschungsintensiven Firmen am Beispiel der Pharmaindustrie
J Mahlich
Die Betriebswirtschaft 65 (4), 396, 2005
202005
Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan
H Kuwabara, K Westerhout, M Treur, K Cerri, J Mahlich, H Yatsuhashi
Journal of medical economics 18 (7), 502-511, 2015
182015
Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data
H Kuwabara, Y Saito, J Mahlich
Neuropsychiatric disease and treatment 11, 935, 2015
182015
Shared decision-making in patients with prostate cancer in Japan: Patient preferences versus physician perceptions
U Schaede, J Mahlich, M Nakayama, H Kobayashi, Y Takahashi, K Saito, ...
Journal of global oncology 4, 1-9, 2017
172017
Drug utilization of Japanese patients diagnosed with schizophrenia: an administrative database analysis
S Cheung, Y Hamuro, J Mahlich, T Nakahara, R Sruamsiri, S Tsukazawa
Clinical drug investigation 37 (6), 559-569, 2017
162017
The technological competencies of Korea’s firms: A patent analysis
B Dachs, JC Mahlich, G Zahradnik
Innovation and technology in Korea, 127-146, 2007
162007
Analysis of contemporary HIV/AIDS health care costs in Germany: Driving factors and distribution across antiretroviral therapy lines
M Treskova, A Kuhlmann, J Bogner, M Hower, H Heiken, HJ Stellbrink, ...
Medicine 95 (26), 2016
152016
Productivity loss of Japanese patients with rheumatoid arthritis–a cross-sectional survey
R Sruamsiri, J Mahlich, E Tanaka, H Yamanaka
Modern rheumatology 28 (3), 482-489, 2018
142018
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20